Evidence map›Paper›PMID 34249475›Full record

ArticleOncoimmunology2021

Prognostic value of the PrP

Alexandre Ghazi, Delphine Le Corre, Camilla Pilati, Julien Taieb, Thomas Aparicio, Audrey Didelot, Shoukat Dedhar, Claire Mulot, Karine Le Malicot, Fatima Djouadi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Integrated multi-omics elucidatesFrontiers in immunology · 2025
    Article
  2. PrPOncogene · 2024
    Article
  3. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  4. Article
  5. Review
  6. Article
  7. Emerging roles of the cellular prion protein (PrPCellular and molecular life sciences : CMLS · 2023
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Alexandre GhaziCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Delphine Le CorreCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Camilla PilatiCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Julien TaiebCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Thomas AparicioDepartment of Gastroenterology and Digestive Oncology, AP-HP, Hôpital Saint-Louis, Université de Paris, Université Paris Diderot, Paris, France.
Audrey DidelotCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Shoukat DedharGenetics Unit, Integrative Oncology, BC Cancer, Vancouver, Canada.
Claire MulotCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Karine Le MalicotFédération Francophone de Cancérologie Digestive, Epicad Inserm, Université de Bourgogne et and Franche Comté, Dijon, France.
Fatima DjouadiCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Aurélien de ReyniesProgramme carte d'identité des tumeurs, Ligue Nationale Contre Le Cancer, Paris, France.
Jean-Marie LaunayAP-HP Service de Biochimie, INSERM U942 Lariboisière Hospital, Paris, France.
Pierre Laurent-PuigCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Sophie Mouillet-RichardCentre de Recherche Des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.ORCID 0000-0002-8950-1949
Inserm · FRDélégation Paris 7 · FRLaboratoire d’immunologie intégrative du cancer · FRLa Ligue Contre le Cancer · FRRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The CMS4 mesenchymal subtype of colorectal cancer (CRC) is associated with poor prognosis and resistance to treatment. The cellular prion protein PrP

Indexed as

Colorectal NeoplasmsHumansIndoleamine-Pyrrole 2,3,-DioxygenasePrion ProteinsPrognosisProtein Serine-Threonine KinasesScaffold Protein ILKIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenasePrion ProteinsProtein Serine-Threonine KinasesScaffold Protein ILKcolorectal cancer molecular classificationIDOintegrin-linked kinaseKynurenine pathwayPrion protein

Identifiers

PMID34249475
PMCPMC8244775
OpenAlexW3174249227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.